Literature DB >> 22210162

Image-guided drug delivery with magnetic resonance guided high intensity focused ultrasound and temperature sensitive liposomes in a rabbit Vx2 tumor model.

Ashish Ranjan1, Genevieve C Jacobs, David L Woods, Ayele H Negussie, Ari Partanen, Pavel S Yarmolenko, Carmen E Gacchina, Karun V Sharma, Victor Frenkel, Bradford J Wood, Matthew R Dreher.   

Abstract

Clinical-grade doxorubicin encapsulated low temperature sensitive liposomes (LTSLs) were combined with a clinical magnetic resonance-guided high intensity focused ultrasound (MR-HIFU) platform to investigate in vivo image-guided drug delivery. Plasma pharmacokinetics were determined in 3 rabbits. Fifteen rabbits with Vx2 tumors within superficial thigh muscle were randomly assigned into three treatment groups: 1) free doxorubicin, 2) LTSL and 3) LTSL + MR-HIFU. For the LTSL + MR-HIFU group, mild hyperthermia (40-41 °C) was applied to the tumors using an MR-HIFU system. Image-guided non-invasive hyperthermia was applied for a total of 30 min, completed within 1h after LTSL infusion. High-pressure liquid chromatography (HPLC) analysis of the harvested tumor and organ/tissue homogenates was performed to determine doxorubicin concentration. Fluorescence microscopy was performed to determine doxorubicin spatial distribution in the tumors. Sonication of Vx2 tumors resulted in accurate (mean = 40.5 ± 0.1 °C) and spatially homogenous (SD = 1.0 °C) temperature control in the target region. LTSL + MR-HIFU resulted in significantly higher tumor doxorubicin concentrations (7.6- and 3.4-fold greater compared to free doxorubicin and LTSL respectively, p<0.05, Newman-Keuls). This improved tumor concentration was achieved despite heating <25% of the tumor volume. Free doxorubicin and LTSL treatments appeared to deliver more drug in the tumor periphery as compared to the tumor core. In contrast, LTSL + MR-HIFU treatment suggested an improved distribution with doxorubicin found in both the tumor periphery and core. Doxorubicin bio-distribution in non-tumor organs/tissues was fairly similar between treatment groups. This technique has potential for clinical translation as an image-guided method to deliver drug to a solid tumor. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22210162      PMCID: PMC3319290          DOI: 10.1016/j.jconrel.2011.12.011

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  44 in total

1.  Mild elevation of body temperature reduces tumor interstitial fluid pressure and hypoxia and enhances efficacy of radiotherapy in murine tumor models.

Authors:  Arindam Sen; Maegan L Capitano; Joseph A Spernyak; John T Schueckler; Seneca Thomas; Anurag K Singh; Sharon S Evans; Bonnie L Hylander; Elizabeth A Repasky
Journal:  Cancer Res       Date:  2011-04-21       Impact factor: 12.701

2.  Mathematical spatio-temporal model of drug delivery from low temperature sensitive liposomes during radiofrequency tumour ablation.

Authors:  Astrid Gasselhuber; Matthew R Dreher; Ayele Negussie; Bradford J Wood; Frank Rattay; Dieter Haemmerich
Journal:  Int J Hyperthermia       Date:  2010       Impact factor: 3.914

Review 3.  Ultrasound-biophysics mechanisms.

Authors:  William D O'Brien
Journal:  Prog Biophys Mol Biol       Date:  2006-08-08       Impact factor: 3.667

4.  Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects.

Authors:  Ana M Ponce; Benjamin L Viglianti; Daohai Yu; Pavel S Yarmolenko; Charles R Michelich; Janet Woo; Marcel B Bally; Mark W Dewhirst
Journal:  J Natl Cancer Inst       Date:  2007-01-03       Impact factor: 13.506

5.  Driving delivery vehicles with ultrasound.

Authors:  Katherine W Ferrara
Journal:  Adv Drug Deliv Rev       Date:  2008-03-30       Impact factor: 15.470

6.  Localised drug release using MRI-controlled focused ultrasound hyperthermia.

Authors:  Robert Staruch; Rajiv Chopra; Kullervo Hynynen
Journal:  Int J Hyperthermia       Date:  2010-12-15       Impact factor: 3.914

7.  Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.

Authors:  M E R O'Brien; N Wigler; M Inbar; R Rosso; E Grischke; A Santoro; R Catane; D G Kieback; P Tomczak; S P Ackland; F Orlandi; L Mellars; L Alland; C Tendler
Journal:  Ann Oncol       Date:  2004-03       Impact factor: 32.976

8.  Blood volume in the pregnant rabbit.

Authors:  H Prince
Journal:  Q J Exp Physiol       Date:  1982-01

9.  Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.

Authors:  Gregory J R Charrois; Theresa M Allen
Journal:  Biochim Biophys Acta       Date:  2004-05-27

10.  Novel temperature-sensitive liposomes with prolonged circulation time.

Authors:  Lars H Lindner; Martin E Eichhorn; Hansjoerg Eibl; Nicole Teichert; Marcus Schmitt-Sody; Rolf D Issels; Marc Dellian
Journal:  Clin Cancer Res       Date:  2004-03-15       Impact factor: 12.531

View more
  92 in total

1.  Targeted drug delivery by high intensity focused ultrasound mediated hyperthermia combined with temperature-sensitive liposomes: computational modelling and preliminary in vivovalidation.

Authors:  Astrid Gasselhuber; Matthew R Dreher; Ari Partanen; Pavel S Yarmolenko; David Woods; Bradford J Wood; Dieter Haemmerich
Journal:  Int J Hyperthermia       Date:  2012       Impact factor: 3.914

Review 2.  MRI-guided focused ultrasound surgery in musculoskeletal diseases: the hot topics.

Authors:  Alberto Bazzocchi; Alessandro Napoli; Beatrice Sacconi; Giuseppe Battista; Giuseppe Guglielmi; Carlo Catalano; Ugo Albisinni
Journal:  Br J Radiol       Date:  2015-11-26       Impact factor: 3.039

3.  Localized delivery of doxorubicin in vivo from polymer-modified thermosensitive liposomes with MR-guided focused ultrasound-mediated heating.

Authors:  Terence Ta; Elizabeth Bartolak-Suki; Eun-Joo Park; Kavon Karrobi; Nathan J McDannold; Tyrone M Porter
Journal:  J Control Release       Date:  2014-08-23       Impact factor: 9.776

Review 4.  Stimuli-responsive nanocarriers for drug delivery.

Authors:  Simona Mura; Julien Nicolas; Patrick Couvreur
Journal:  Nat Mater       Date:  2013-11       Impact factor: 43.841

Review 5.  Non-viral delivery systems for CRISPR/Cas9-based genome editing: Challenges and opportunities.

Authors:  Ling Li; Shuo Hu; Xiaoyuan Chen
Journal:  Biomaterials       Date:  2018-04-18       Impact factor: 12.479

6.  Sequential HIFU heating and nanobubble encapsulation provide efficient drug penetration from stealth and temperature sensitive liposomes in colon cancer.

Authors:  Joshua VanOsdol; Kalyani Ektate; Selvarani Ramasamy; Danny Maples; Willie Collins; Jerry Malayer; Ashish Ranjan
Journal:  J Control Release       Date:  2016-12-30       Impact factor: 9.776

7.  Pulsed focused ultrasound lowers interstitial fluid pressure and increases nanoparticle delivery and penetration in head and neck squamous cell carcinoma xenograft tumors.

Authors:  Ali Mohammadabadi; Ruby N Huynh; Aniket S Wadajkar; Rena G Lapidus; Anthony J Kim; Christopher B Raub; Victor Frenkel
Journal:  Phys Med Biol       Date:  2020-06-22       Impact factor: 3.609

8.  Thermal combination therapies for local drug delivery by magnetic resonance-guided high-intensity focused ultrasound.

Authors:  Nicole Hijnen; Esther Kneepkens; Mariska de Smet; Sander Langereis; Edwin Heijman; Holger Grüll
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-31       Impact factor: 11.205

Review 9.  Thermosensitive liposomes for localized delivery and triggered release of chemotherapy.

Authors:  Terence Ta; Tyrone M Porter
Journal:  J Control Release       Date:  2013-04-11       Impact factor: 9.776

Review 10.  Magnetic Resonance-Guided Drug Delivery.

Authors:  Andrew S Mikhail; Ari Partanen; Pavel Yarmolenko; Aradhana M Venkatesan; Bradford J Wood
Journal:  Magn Reson Imaging Clin N Am       Date:  2015-07-09       Impact factor: 2.266

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.